Answers are grounded in this paper and cite their sources.
Acute myeloid leukaemia (AML) was an incurable disease prior to allogeneic haematopoietic cell transplantation (allo-HCT), which was proven to be a potent cellular immunotherapy-approach. However, allo-HCT has major side effects, with disease relapse presenting as a frequent complication. Novel immunotherapies aim to reduce toxicity and increase the anti-leukaemia activity of allo-HCT. Technological advancements in genetic engineering approaches enable potent immunotherapeutic activity while limiting toxicities. A biology-driven application of small molecules that target AML vulnerabilities holds promise to enhance anti-leukaemia immunotherapy. Extensive preclinical testing of these approaches is essential to reduce toxicity and to find the ideal combination partners for future clinical testing. • Engineered shielding of HSCs enables potent immunotherapies against AML, while limiting ‘on-target, off-tumour’ toxicities. • Integrated multi-omics uncover target antigens that allow for selective targeting of leukaemic cells and sparing of HSCs. • Transcriptional reprogramming of effector cell immunotherapy potentiates anti-leukaemic function. • Pharmacological immunotherapies hold promise for immediate clinical translation and durable clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Lysandrou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: